Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.
02 juil. 2024 03h00 HE
|
Hofseth Biocare ASA
Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate...
Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
11 juin 2024 03h00 HE
|
Hofseth Biocare ASA
Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China. Shanghai-based Lithy has entered into...
Hofseth Biocare ASA: Annual General Meeting completed
10 mai 2024 08h30 HE
|
Hofseth Biocare ASA
Hofseth BioCare ASA held its Annual General Meeting on 10 May 2024. 270,174,810 shares, amounting to 68.38 per cent of the share capital, were represent in the meeting or by proxy. All proposals were...
Hofseth Biocare ASA: NOTICE OF ANNUAL GENERAL MEETING 2024
19 avr. 2024 07h00 HE
|
Hofseth Biocare ASA
The Annual General Meeting of Hofseth BioCare ASA for 2024 will be held at the company's premises at Keiser Wilhelms gate 24, 6003 Ålesund, on 10 May 2024 at 13:00 CET. The notice of the Annual...
Hofseth Biocare ASA: HBC ANNUAL REPORT 2023
19 avr. 2024 02h00 HE
|
Hofseth Biocare ASA
The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2023 and the Company has today published the Annual Report and Sustainability Report for 2023. Please...
Hofseth Biocare ASA: UPDATED COMPANY PRESENTATION
21 mars 2024 05h40 HE
|
Hofseth Biocare ASA
Please find the HBC Company Presentation attached. For further information, please contact: James Berger, Chief Commercial Officer of Hofseth BioCare ASA Phone: +41 79 950 10 34 E-mail:...